Kronik hepatit B enfeksiyonunda lamivudin monoterapisi, interferon alfa monoterapisi ve kombinasyon tedavisi
2006
Background/aim: This study aims to evaluate the efficacy of lamivudine and interferon alpha monotherapies and their combination in HBeAgpositive and HBeAg-negative chronic hepatitis B. Materials and methods: Between 2002 and 2004, a total of 128 patients [65 HBeAgpositive and 63 HBeAg-negative] were enrolled; 21 patients received lamivudine monotherapy (HBeAg-positive = 11, HBeAg-negative = 10), 40 received interferon-alpha monotherapy (HBeAg-positive = 23, HBe- Ag-negative = 17), and 67 received the combination (HBeAg-positive = 29, HBeAg-negative = 38). The virologic responses, biochemical responses, and seroconversion rates were evaluated after 6 months. Results: In HBeAg-positive patients, HBV DNA loss was observed in 36.4%, 47.8% and 89.7% of patients after lamivudine monotherapy, interferon monotherapy and combination therapy, respectively (p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI